Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:17:08.022Z.
Calculation as of: 2026-10-06T14:17:08.022Z.
Quote observation: 2026-10-06T14:13:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 581b2fbaae035830ca35d06372124b56c7048e0f0ab23ef832a371d1053372ba
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.43M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.18M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.63M | N/A | 245.86 | 105.92 | 78.24 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.74M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $12.05M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $11.88M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $11.87M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.40
Forward EPS (Est.)
$-1.11
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
